Showing 25 of 856 items meeting your criteria.
| | Type | Category | Supplier | |
|---|
| |
 | ImmunoMetrix™ is a premier line of monoclonal antibodies originated and rigorously characterised by the Clinical Proteomic Tumour Analysis Consortium (CPTAC) standards. By combining the CPTACs unrivalled validation standards with Leincos 30+ years of manufacturing excellence, we provide the most reliable affinity reagents available for cancer research. |
Documents | Antibodies | Leinco Technologies | |
 | As organoid models grow in complexity, the demand for antibodies that can perform in dense 3D environments is critical. Leincos catalog is engineered to provide high penetration, low background, and physiological safety for tumor-immune co-cultures and spatial phenotyping. |
Documents | Antibodies | Leinco Technologies | |
 | TargetMol offers hundreds of products for disease modelling, covering a wide range of disease models including cancer, neurological disorders, immune and inflammatory conditions, endocrine and metabolic diseases, as well as cardiovascular diseases. |
Documents | Catalogue | TargetMol | |
 | TargetMol, as a professional one-stop platform for drug discovery, offers a variety of products related to Endocrinology and Metabolism. |
Documents | Metabolism | TargetMol | |
 | HTS, which emerged in the 1990s, is a new model for drug discovery that integrates advanced technology in chemistry, biology, bioinformatics and automation. |
Documents | Drug Discovery | TargetMol | |
 | As a one-stop drug screening expert, TargetMol offers stable products with a wide variety, providing a range of inhibitors & agonists, recombinant proteins, compound libraries and drug-like compound libraries related to cardiovascular diseases. |
Documents | Cardiovascular | TargetMol | |
 | TargetMol offers a catalogue of small molecules, custom synthesis, CADD and compound libraries. |
Documents | Small Molecules | TargetMol | |
 | Computer-Aided Drug Design (CADD) is a technology that utilises computer techniques to discover and optimise active lead compounds into candidate drugs. Artificial Intelligence-Driven Drug Discovery (AIDD) utilises AI technology to improve the efficiency and success rate of the drug discovery and design process. |
Documents | Drug Discovery | TargetMol | |
 | TargetMol provides a range of kits for life science research. |
Documents | Kits | TargetMol | |
 | Drug-Like Compounds, as a class of small molecules with drug potential, serve as an important source for small-molecule drug discovery. They are typically derived from existing drugs through structural modifications or improvements to achieve better efficacy or reduce adverse effects. Drug-like compounds help researchers gain insights from existing drugs, enabling the rapid development of novel therapeutics and improving research and development efficiency. |
Documents | Small Molecules | TargetMol | |
 | TargetMol currently offers over 14,500 recombinant protein products, including cytokines, growth factors, receptor proteins, enzymes and viral proteins. |
Documents | Recombinant Proteins | TargetMol | |
 | TargetMol currently offers more than 3,000 inhibitory antibody products, including biosimilar antibodies, bispecific antibodies, antibody-drug conjugates (ADCs) and anti-mouse/anti-rat in vivo antibodies. |
Documents | Antibodies | TargetMol | |
 | Protein-protein interactions (PPIs) are the cornerstone of life processes and a "goldmine" of targets for next-generation drug development. Yet, PPI-targeted drug discovery often hits a wall: groundbreaking mechanisms are identified, but validated lead compounds remain elusive—leaving researchers with "no ingredients to cook with." |
Documents | Service | TargetMol | |
 | TargetMol offers over 14,500 detection antibodies covering a wide range of research areas and classic signalling pathways. |
Documents | Antibodies | TargetMol | |
 | TargetMol provides inhibitors, agonists and compound libraries targeting ion channels. |
Documents | Small Molecules | TargetMol | |
 | Inhibitors & Agonists, Natural Products, Recombinant Proteins, PROTAC, Peptides, Dye Reagents, Inhibitory Antibody & ADC, Disease Modelling Products, Kits and Antibodies. |
Documents | Supplier Introduction | TargetMol | |
 | TargetMol currently offers over 1,600 ADC-related products, covering ADCs as well as their corresponding antibodies, payloads, linkers, and related recombinant proteins. |
Documents | Drug Discovery | TargetMol | |
 | hPCMA is an innovative human placenta-derived material with tunable mechanical properties, offering collagen-rich microenvironment for 3D cell culture that supports cell adhesion, growth and proliferation. |
Documents | Cell Culture | Metatissue | |
 | Redefining T-cell activation. |
Documents | Cell Culture | Bio-ReCell | |
 | T-cell activation reagent, based on non-magnetic beads. |
Documents | Cell Culture | Bio-ReCell | |
 | The Atract™ Kit produces a fast and strong activation response from naïve T cells, promoting high proliferation and expansion of activated cells. |
Documents | Cell Culture | Bio-ReCell | |
 | SAFETY DATA SHEET for Atract™ T-Cell Activation Kit V2, CD2/CD3/CD28 |
Documents | Datasheets | Bio-ReCell | |
 | SAFETY DATA SHEET for Atract™ T-Cell Activation Kit V1, CD3/CD28 |
Documents | Datasheets | Bio-ReCell | |
 | Advancing science with reliable, high-performance qPCR |
Documents | PCR Kits | Applied Biological Materials (abm) | |
 | abms mycoplasma detection kits provide reliable contamination monitoring across routine and critical workflows. Designed to support experimental accuracy and reproducibility, they help ensure confidence in cell culture-based research. |
Documents | PCR Kits | Applied Biological Materials (abm) | |